Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Cannabis remains the most commonly used illicit substance world-wide, with international estimates indicating that 2.8%-4.5% of the global population use cannabis each year. This prevalence rate has not changed substantially in the past decade and there is no indication that it will do so in the next decade. In line with this, many prominent organizations and individuals have acknowledged that the “war on drugs” has failed and are now calling for a rethink on drug-related policy and legal frameworks. With a growing number of jurisdictions across the world heeding this call and introducing legislation to decriminalize or legalize cannabis use, it is essential that any changes to legal frameworks and public health policies are based on the best available scientific evidence. To facilitate the adoption of an evidence-based approach to cannabis policy, the aim of this Research Topic was to gather a comprehensive body of research to clarify the current state of evidence relating to cannabis use. Of interest were articles addressing the following questions: • How do we study cannabis use? (e.g., recruitment; measuring dose/use; assessing dependence/problematic use; confounding; translation of findings from animal studies) • What do we know about cannabis use? (e.g., patterns, contexts, methods of use) • What do we know about people who use cannabis? (e.g., who uses cannabis and why) • What are the social settings, norms and cultural values that go along with cannabis use? • How is problematic cannabis use, as opposed to mere use, defined, judged and constructed in different societies? • What do we know about the effects/outcomes of cannabis use? (e.g., acute, short- and long-term; harms/ benefits) • What do we know about the factors associated with the initiation, continuance and cessation of cannabis use? • What do we know about the medicinal use of cannabis? (e.g., who uses medicinally and why; efficacy/effectiveness in different clinical populations; comparison with other medications) • What do we know about treatment for people who engage in problematic cannabis use? (e.g., who seeks/is referred to treatment and why; efficacy and effectiveness) • What do we know about cannabis? (e.g., pharmacodynamics/pharmacokinetics of different strains, cultivation, preparation and consumption methods) • How do policy and legal frameworks impact on the people who use cannabis? • What is the future for cannabis research? (e.g., potential avenues for future research; aspects needing more attention; innovative approaches; political/funding issues affecting cannabis research)

Cannabis --- marijuana --- Cannabinoids --- Addiction --- psychosis --- Affective disorders anxiety --- drug policy --- legalization --- normalization

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Many macro and micro species, from terrestrial and aquatic environments, produce structurally unique compounds and, in many countries, still are the primary sources of medicines. In fact, secondary metabolites are an important source of chemotherapeutic agents but are also lead compounds for synthetic modification and the optimization of biological activity. Therefore, the exploitation of secondary metabolites, or their inspired synthetic compounds, offers excellent opportunities for the pharmaceutical industry. This Medicines Special Issue focuses on the great potential of secondary metabolites for therapeutic application. The Special Issue contains 16 articles reporting relevant experimental results, and an overview of bioactive secondary metabolites, their biological effects, and new methodologies that improve and accelerate the process of obtained lead compounds with regard to new drug development. We would like to thank all 83 authors, from all over the world, for their valuable contributions to this Special Issue.

Juniperus --- secondary metabolites --- diterpenes --- flavonoids --- lignans --- cytotoxic --- antitumor --- antibacterial --- amentoflavone --- deoxypodophyllotoxin --- frankincense --- Boswellia --- cembranoids --- cneorubenoids --- boswellic acids --- molecular docking --- Scabiosa --- flavonoids --- iridoids --- pentacyclic triterpenoids --- antioxidant --- anti-inflammatory --- antibacterial --- anticancer --- Cordyceps militaris --- xanthine oxidase --- antioxidant --- antibacterial --- cordycepin --- GC-MS --- Artemisia species --- Artemisia vachanica --- artemisinin --- HPLC-PAD --- Tajikistan --- Malus x domestica --- Tuscany --- ancient varieties --- nutraceutics --- antioxidants --- polyphenols --- sugars --- pectin --- defensins --- secondary metabolites --- plant defense --- antimicrobial and anticancer activity --- medicine --- innate immunity --- cannabis --- cannabinoids --- therapeutics --- toxicology --- analytical determination --- legalization --- natural products --- biosynthetic gene clusters --- secondary metabolites --- antiSMASH --- Mitragyna speciosa --- kratom --- secondary metabolites --- therapeutic uses --- toxicology --- analysis --- Maytenus chiapensis --- Celastraceae --- quinonemethide triterpenoids --- pristimerin --- tingenone --- HPLC-PDA --- Ocimum sanctum --- Lamiaceae --- (-)-rabdosiin --- cytotoxic activity --- triterpenoids --- phenolic derivatives --- nanoemulsion --- essential oils --- vector control --- infectious diseases --- TCM --- phytochemistry --- LC-MS/MS --- antioxidant activity --- ABTS --- DPPH --- FRAP --- ascorbic acid --- EGCG --- total phenolics --- antimicrobial activity --- sargaquinoic acid --- sarganaphthoquinoic acid --- antiplasmodial --- malaria --- PPAR-? --- sargahydroquinoic acid --- sarganaphthoquinoic acid --- sargachromenoic acid --- inflammation --- bowel diseases --- secondary metabolites --- biological activities --- medicinal applications --- plants --- seaweeds